In two phase 3 clinical trials, retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon triple-hormone receptor agonist, demonstrated significant weight loss and clinically meaningful improvements in health outcomes in people living with obesity and type 2 diabetes
Researchers found that epithalon significantly inhibited the development of tumors in rats exposed to natural light [7]
Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, not a pure GLP-1 medication
Table of Contents If youre asking how much weight can you lose with GLP-1 injections, the answer may be more encouraging than you think
Toxicol1970 46
In other words, neither Ozempic nor Mounjaro is likely to be covered for weight loss, but they could both be covered for Type 2 diabetes, because they are FDA approved for that use
